What does cbqv stand for in pegfilgrastim?
Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on Jan 12, 2021.
- The “cbqv” suffix is found in the biosimilar name for Udenyca (pegfilgrastim-cbqv), a biologic drug used to prevent neutropenia (a lack of certain white blood cells) caused by receiving chemotherapy. The suffix is used to distinguish its name from the original reference product, in this case Neulasta (pegfilgrastim), which has no suffix.
- The suffix on biosimilars helps healthcare providers and patients realize the medicine is an approved biosimilar, but has no specific meaning.
- All biosimilars share the same core name but each one has a different suffix. The suffix is always composed of 4 letters that are attached to the original biologic name with a hyphen, assigned by the FDA.
Biosimilars are FDA-approved drugs that are highly similar to their brand-name counterparts. Biosimilars are biologics for which there are no clinically meaningful differences in terms of safety, purity, and potency. These products are generally derived from living organisms, such as plants, animals, human cells, or microorganisms. Biosimilars are expected to yield billions in cost-savings for the healthcare system and consumers.
Structurally, biologics are large and complex structures that are difficult to manufacture and replicate. Biosimilars are not automatically considered interchangeable with the reference product. A list of approved biosimilars can be found in the FDA’s Purple Book.
Learn more: What Are Biosimilars? Top Facts You May Not Know
There are 4 biosimilars for Neulasta (pegfilgrastim), all of which have a unique suffix.
- In June 2018, the FDA approved Mylan's and Biocon’s Fulphila (pegfilgrastim-jmbd).
- In November 2018, Udenyca (pegfilgrastim-cbqv), from Coherus BioSciences, received FDA approval.
- Ziextenzo (pegfilgrastim-bmez), from Sandoz, was approved in November 2019.
- Nyvepria (pegfilgrastim-apgf) was cleared in June 2020.
Like Neulasta, all of these products are PEGylated growth colony-stimulating factors used to reduce the duration of febrile neutropenia (fever or other signs of infection with a low count of white blood cells) in patients treated with chemotherapy in certain types of cancer. These agents help lower the risk of infection due to a low white blood cell count.
This is not all the information you need to know about Udenyca (pegfilgrastim-cbqv) for safe and effective use. Review the full Udenyca information here, and discuss this information and any questions you have with your doctor or other health care provider.
- Nonproprietary naming of biological products—guidance for industry. U.S Food and Drug Information (FDA). Draft guidance. https://www.fda.gov/media/93218/download
- Purple Book. U.S Food and Drug Information (FDA). Database of Licensed Biological Products. https://purplebooksearch.fda.gov/
- Peters G, Hennessey E. Naming of biological products. US Pharm. 2020;45(6)33-36. https://www.uspharmacist.com/article/naming-of-biological-products
Related Medical Questions
- Why do you take Claritin with Neulasta?
- When can I remove the Neulasta Onpro?
- How many biosimilars have been approved in the United States?
- When does Neulasta reach peak levels?
- How do you increase white blood cells during chemo?
- How long do the side effects of the Neulasta (pegfilgrastim) shot last?
- Does Neulasta cause bone pain?